BASF picks up omega-3 maker; Sigma dislikes Pfizer distributing direct to pharmacies;

> Zhejiang Hisun Pharmaceutical has a deal to commercially manufacture Celsion's heat-activated liposomal encapsulation of doxorubicin, used for the treatment of various cancers. Story

> BASF has bought Equateq, which has a manufacturing plant in Scotland with 47 employees where its makes highly concentrated omega-3 fatty acids for the pharmaceutical industry. Item

> The drug wholesaler Sigma Pharmaceuticals is raising concerns in Australia that a policy requiring drugs to be available within 24 hours is in jeopardy if companies follow Pfizer's lead in bypassing wholesalers and delivering drugs directly to pharmacies. Story

> Tibet Pharmaceuticals ($TBET), which manufactures traditional Tibetan medications, has an agreement with wholesaler Anhui Taihe Pharmaceutical Group, which has a network across 16 provinces and municipalities in China. Announcement

> India's top drug regulator is being investigated for letting pharmaceutical manufacturers, including some of the world's largest, go to market with drugs with little or no clinical testing. Story

> Jubilant HollisterStier has nailed down 5-year agreements to manufacture and distribute two products for Lantheus Medical Imaging. Item

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.